An historical review of glucocorticoid treatment in sepsis. Disease pathophysiology and the design of treatment investigation

Sepsis

Volumn 3, Issue 1, 1999, Pages 21-38

  Meduri, G Umberto ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b NONE   (United States)

Author keywords

Acute respiratory distress syndrome; Complications; Disease; Glucocorticoid receptor; Glucocorticoids; Infection; Sepsis; Syndrome; Transcription factors; Treatment

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; CELL ADHESION MOLECULE; CORTICOTROPIN[4-10]; ENDOTHELIN 1; GLUCOCORTICOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; LIPOCORTIN 1; NITRIC OXIDE SYNTHASE; PHOSPHOLIPASE A2; TUMOR NECROSIS FACTOR ALPHA;

ACUTE RESPIRATORY TRACT DISEASE; CONFERENCE PAPER; DOSE CALCULATION; DRUG EFFICACY; HISTORY OF MEDICINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPATHOLOGY; LONG TERM CARE; SEPSIS; STEROID THERAPY; TREATMENT OUTCOME;

EID: 0032826595     PISSN: 13850229     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009870524359     Document Type: Conference Paper

References (132)

1. Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A. Reversal of late septic shock with supraphysiological doses of hydrocortisone. Crit Care Med 1998;26:645-650.
2. Briegel J, Forst H, Haller M, Schelling G, Kilger E, Kuprat G, Hemmer B, Hummel T, Lenhart A, Heyduck M, Stoll C, Peter K. Stress doses of hydrocortisone reverse hyperdynamic septic shock: A prospective randomized, double-blind, single-center study. Crit Care Med 1999;27:723.
3. Chawla K, Kupfer Y, Goldman I, Tessler S. Hydrocortisone reverses refractory septic shock. Crit Care Med 1999;27:A33 (abstract)
4. Meduri GU, Headley S, Carson S, Umberger R, Kelso T, Tolley E. Prolonged methylprednisolone treatment improves lung function and outcome of unresolving ARDS. A randomized, double-blind, placebo-controlled trial. JAMA 1998;280:159-165.
5. Lucas CE, Ledgerwood AM. The cardiopulmonary response to massive doses of steroids in patients with septic shock. Arch Surg 1984;119:537-541.
6. Sprung CL, Caralis PV, Marcial EH, Pierce M, Gelbard MA, Long WM, Duncan RC, Tendler MD, Karpf M. The effects of high-dose corticosteroids in patients with septic shock. N Engl J Med 1984;311:1137-1143.
7. Bone RC, Fisher CJ, Clemmer TP, et al. A controlled trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987;317:653-658.
8. Hinshaw L, Peduzzi P, Young E, Sprung C, Shatney C, et al. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 1987;317:659-665.
9. Luce JM, Montgomery AB, Marks JD, Turner J, Metz CA, Murray JP. Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am Rev Respir Dis 1988;138:62-68.
10. Bernard GR, Luce JM, Sprung CL, Rinaldo JE, Tate RM, Sibbald WJ, Kariman K, Higgins S, Bradley R, Metz CA, Harris TR, Brigham KL. High-dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med 1987;317:1565-1570.
11. Lefering R, Neugebauer EAM. Steroid controversy in sepsis and septic shock: A meta-analysis. Crit Care Med 1995;23:1294-1303.
12. Cronin L, Cook DJ, Carlet J, Heyland DK, King D, Math B, Lansang MAD, Fisher CJ. Corticosteroid treatment for sepsis: A critical appraisal and meta-analysis of the literature. Crit Care Med 1995;23:1430-1439.
13. Meduri GU, Chrousos GP. Duration of glucocorticoid treatment and outcome in sepsis: Is the right drug used the wrong way? Chest 1998;114:355-360.
14. Cotran RS, Kumar V, Robbins SL. Cellular injury and cellular death. In: Cotran RS, Kumar V, Robbins SL, eds. Pathologic Basis of Disease. Philadelphia: W.B. Saunders, 1994;1-34.
15. Stedman's Medical Dictionary, Baltimore: Williams and Wilkins, 1990. Ed. 25
16. Tolley EA. Causal modeling of infection in the activated host: Implications for critical care and clinical investigations. Sepsis 1999;(in press)
17. Clinical Pharmacokinetics, Philadelphia: Williams and Wilkins, 1995. Ed. 3
18. Perla D, Marmorston J. Suprarenal cortical hormone and salt in the treatment of pneumonia and other severe infections. Endocrinology 1940;27:367-374.
19. Selye H. The general adaptation syndrome and the diseases of adaptation. J Clin Endo 1946;6:117-230.
20. Munck A, Guyre PM, Holbrook NJ. Physiological functions of glucocorticoids in stress and their relation to pharmacological actions. Endocrine Rev 1984;5:25-44.
21. Kass EH, Ingbar SH, Finland M. Effects of adrenocorticotrophic hormone in pneumonia: Clinical, bacteriological and serological studies. Ann Intern Med 1950;33: 1081-1098.
22. Kinsell LW, Jahn JP. The use of corticoids in association with antibiotics in the management of unusually severe infections. Ann NY Acad Sci 1955;61:397-407.
23. Kass EH, Finland M. Adrenocortical hormones in infection and immunity. Ann Rev Microbiol 1953;7:361-388.
24. Spink WW. Adrenocortical steroids in the management of selected patients with infectious diseases. Ann Intern Med 1960;53:1-32.
25. Breen GE, Talukdar PK. Corticosteroids in acute infections. Lancet 1965;1:158-160.
26. Thomas L. The effects of cortisone and adrenocorticotropic hormone on infection. Ann Rev Med 1952;3:1-24.
27. Hahn EO, Houser HB, Rammelkamp CH, et al. Effect of cortisone on acute streptococcal infections and post-streptococcal complications. J Clin Invest 1951;30:274-281.
28. Lepper MH, Spies HW The use of intravenous hydrocortisone as supplemental treatment in acute bacterial meningitis. Antibiot Ann 1956;447-454.
29. Kass EH, Finland M. Adrenocortical hormones and the management of infection. Ann Rev Med 1957;8:1-18.
30. Wagner HN Jr, Bennett IL Jr, Lasagna L, Cluff LE, Rosenthal MB, Mirick GS. The effect of hydrocortisone upon the course of pneumococcal pneumonia treated with penicillin. Bull Johns Hopkins Hosp 1956;98:197-215.
31. Spink WW. ACTH and adrenocorticosteroids as therapeutics adjuncts in infectious diseases. N Engl J Med 1957; 257:979-983.
32. Spink WW. ACTH and adrenocorticosteroids as therapeutic adjuncts in infectious diseases (Pt. 2). N Engl J Med 1957; 257:1031-1035.
33. Antopol W, Quittner H. The changing pattern of infectious processes under the influence of cortisone. J Mount Sinai Hosp 1952;19:91-105.
34. Jahn JP, Boling L, Meagher TR, Peterson HH, et al. The combination of ACTH-cortisone-hydrocortisone with antibiotics in the management of overwhelmingly sever infections. J Pediatr 1954;44:640-657.
35. Lepper MH, Spies HW. A clinical study of the use of cortisone, hydrocortisone, and corticotropin in the treatment of seriously ill patients with infections. Antibiot Ann 1956;447-454.
36. Aikawa JK, Harrell GT. Effect of cortisone acetate on experimental Rocky Mountain Spotted Fever in the guinea pig. Proc Soc Exp Biol Med 1953;82:698-701.
37. Robinson HJ, Mason RC, Smith AL. Beneficial effects of cortisone on survival of rats infected with D. pneumoniae. Proc Soc Exp Biol Med 1953;84:312-314.
38. Singer I. The effect of cortisone on infections with plasmodium berghei in the white mouse. J Infect Dis 1954;94: 164-172.
39. Wilckens T, De Rijk R. Glucocorticoids and immune function: unknown dimensions and new frontiers. Immunol Today 1997;18:418-424.
40. Wiegers GJ, Reul JM. Induction of cytokine receptors by glucocorticoids: Functional and pathological significance. Trends Pharmacol Sci 1998;19:317-321.
41. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1995; 332:1351-1362.
42. Melby JC, Egdahl RH, Spink WW Secretion and metabolism of cortisol after injection of endotoxin. J Lab Clin Med 1960;56:50-62.
43. Melby JC, Egdahl RH, Bossenmaier IC, Spink WW. Suppression by cortisol of increased serum-transaminase induced by endotoxin. Lancet 1959;1:441-444.
44. Melby JC, Spink WW. Comparative studies on adrenalcortical function and cortisol metabolism in healthy adults and in patients with shock due to infection. J Clin Invest 1958; 37:1791-1798.
45. Weitzman S, Berger S. Clinical trial design in studies of corticosteroids for bacterial infections. Ann Intern Med 1974;81:36-42.
46. Levitin H, Kendrick MI, Kass EH. Effect of route of administration on protective action of corticosterone and cortisol against endotoxin. Proc Soc Exp Biol Med 1956;93:306-309.
47. Lillehei RC, Longerbeam JK, Bloch JH. Physiology and therapy of bacteremic shock. Am J Cardiol 1963;599-613.
48. Vaughn D, Kirschbaum TH, Bersentes T, Assali NS. Effects of corticosteroid hormones on regional circulation in endotoxin shock. Proc Soc Exp Biol Med 1967;124:760-764.
49. Motsay GJ, Alho A, Jaeger T, Dietzman RH, Lillehei RC. Effects of corticosteroids on the circulation in shock: experimental and clinical results. Fed Proc 1970;29:1861-1873.
50. Prager R, Kirsh MM, Dunn E, Nishiyama R, Straker J, Lee R, Sloan H. The benefits of corticosteroids in endotoxic shock. Ann Thorac Surg 1975;142-152.
51. Schuler JJ, Erve PR, Schumer W. Glucocorticoid effect on hepatic carbohydrate metabolism in the endotoxin-shocked monkey. Ann Surg 1976;183:345-354.
52. Michie HR, Monogue KR, Spriggs DR, et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 1988;318:1381-1386.
53. Zanetti G, Heumann D, Gerain J, Kohler J, Abbet P, Barras C, Lucas R, Glauser MP, Baumgartner JD. Cytokine production after intravenous or peritoneal gram-negative bacterial challenge in mice. Comparative protective efficacy of antibodies to tumor necrosis factor-a and to lipopolysaccharide. J Immunol 1992;148:1890-1897.
54. Calandra T, Baumgartner JD, Grau GE, Wu MM, Lambert PH, Schellekens J, Verhoef J, Glauser MP, the Swiss-Dutch J5 Immunoglobulin Study Group. Prognostic values of tumor necrosis factor/cachetin, interleukin-1, interferon-a, and interferon-g in the serum of patients with septic shock. J Infect Dis 1990;161:982-987.
55. Pink MP, Baggs AG. Animal models of sepsis and septic shock. In: Fein AM, Abraham EM, Balk RA, et al., eds. Sepsis and Multiorgan Failure. Baltimore: Williams & Wilkins, 1997;596-613.
56. Schumer W. Steroids in the treatment of clinical septic shock. Ann Surg 1976;184:333-339.
57. Motsay GJ, Dietzman RH, Ersek RA, Lillehei RC. Hemodynamic alterations and results of treatment in patients with gram-negative septic shock. Surgery 1970;67:577-583.
58. Hinshaw LB, Coalson JJ, Benjamin BA, Archer LT, Bellar BK, Kling OR, Hasser EM, Phillips RW. Escherichia coli shock in the baboon and the response to adrenocorticosteroid treatment. Surg, Gynecol & Obstet 1978;147:545-557.
59. Sjolin J. High-dose corticosteroid therapy in human septic shock: Has the jury reached a correct verdict? Circulatory Shock 1991;35:139-151.
60. Hinshaw LB, Keller BK, Archer LT, Flournoy DJ, White GL, Phillips RW. Recovery from lethal escherichia coli shock in dogs. Surg, Gynecol & Obstet 1979;149:545-553.
61. 100 septic shock following steroid/antibiotic therapy. J Surg Res 1980;28:151-170.
62. Hinshaw LB, Archer LT, Beller-Todd BK, Benjamin B, Flournoy DJ, Passey R. Survival of primates in lethal septic shock following delayed treatment with steroid. Circulatory Shock 1981;8:291-300.
63. McCabe WR, Jackson GG. Gram-negative bacteremia. I. Etiology and ecology. II. Clinical, laboratory, and therapeutic observation. Arch Intern Med 1962;110:847-864.
64. Barber AE, Coyle SM, Marano MA, Fischer E, Calvano SE, Fong Y, Moldawer LL, Lowry SF. Glucocorticoid therapy alters hormonal and cytokine responses to endotoxin in man. J Immunol 1993;150:1999-2006.
65. Weil MH, Allen KS. The effect of steroids on shock due to endotoxin. In: Mills LC, ed. Inflammation and disease of connective tissue; a Hahnemann symposium. Philadelphia: Saunders, 1961;768-778.
66. Pitcairn M, Schuler J, Erve PR, Holtzman S, Schumer W. Glucocorticoid and antibiotic effect on experimental gram-negative bacteremic shock. Arch Surg 1975;110:1012-1015.
67. Greisman SE. Experimental gram-negative bacterial sepsis: optimal methylprednisolone requirements for prevention of mortality not preventable by antibiotics alone. Proc Soc Exp Biol Med 1982;170:436-442.
68. Jones RL, King EG. The effects of methylprednisolone on oxygenation in experimental hypoxemic respiratory failure. J Trauma 1975;15:297-303.
69. Hesterberg TW, Last JA. Ozone-induced acute pulmonary fibrosis in rats - Prevention of increased rates of collagen synthesis by methylprednisolone. Am Rev Respir Dis 1981;123:47-52.
70. Hakkinen PJ, Schmoyer RL, Witschi HP. Potentiation of butylated-hydroxytoluene-induced acute lung damage by oxygen. Effects of prednisolone and indomethacin. Am Rev Respir Dis 1983;128:648-651.
71. Kehrer JP, Klein-Szanto AJP, Sorensen EMB, Pearlman R, Rosner MH. Enhanced acute lung damage following corticosteroid treatment. Am Rev Respir Dis 1984;130: 256-261.
72. Ashbaugh DG, Maier RV. Idiopathic pulmonary fibrosis in adult respiratory distress syndrome. Diagnosis and treatment. Arch Surg 1985;120:530-535.
73. Meduri GU, Chinn AJ, Leeper KV, Wunderink RG, Tolley E, Winer-Muram HT, Khare V, El Torky M. Corticosteroid rescue treatment of progressive fibroproliferation in late ARDS. Patterns of response and predictors of outcome. Chest 1994;105:1516-1527.
74. Briegel J, Kellermann W, Forst H, Haller M, Bittl M, Hoffmann GE, Buchler M, Uhl W, Peter K, The Phospholipase A2 Study Group. Low-dose hydrocortisone infusion attenuates the systemic inflammatory response syndrome. Clin Invest 1994;72:782-787.
75. Annane D, Raphael JC, Gajdos P. Are endogenous glucocorticoid levels adequate in septic shock? Inten Care Med 1996;22:711-718.
76. Meduri GU, Tolley A, Chin A, Stentz F, Postlethwaite A. Procollagen type I & III aminoterminal propeptide levels during acute respiratory distress syndrome and in response to prolonged methylprednisolone treatment. Am J Resp Crit Care Med 1998;158:1432-1441.
77. Meduri GU. Levels of evidence for the pharmacological effectiveness of prolonged methylprednisolone treatment in unresolving acute respiratory distress syndrome. Chest 1999;116:116S-118S.
78. Suffredini AF. Current prospects for treatment of clinical sepsis. Crit Care Med 1994;22:S12-S18.
79. Udelsman R, Holbrook NJ. Endocrine and molecular responses to surgical stress. Curr Probl Surg 1994;31:653-720.
80. Barnes PJ, Karin M. Nuclear factor-kB - A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-1071.
81. Strieter RM, Lukacs NW, Standiford TJ, Kunkel SL. Cytokines and lung inflammation: Mechanisms of neutrophil recruitment to the lung. Thorax 1993;48:765-769.
82. Van Der Poll T, Buller HR, Cate HT, Wortel CH, Bauer KA, Van Deventer SJK, Hack Ce, Sauerwein HP, Rosenberg RD, Cate JW. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990;322:1622-1627.
83. Elias JA, Freundlich B, Kern JA, Rosenbloom J. Cytokine networks in the regulation of inflammation and fibrosis in the lung. Chest 1990;97:1439-1445.
84. King RJ, Jones MB, Minoo P. Regulation of lung cell proliferation by polypeptide growth factors. Am J Physiol 1989;257:L23-L38.
85. Postlethwaite AE, Seyer JM. Stimulation of fibroblast chemotaxis by human recombinant tumor necrosis factor α (TNF-α) and a synthetic TNF-α 31-68 peptide. J Exp Med 1990;172:1749-1756.
86. Meduri GU, Estes RJ. Pathogenesis of ventilator-associated pneumonia: The lower respiratory tract. Inten Care Med 1995;21:452-461.
87. Perlstein RS, Whitnall MH, Abrams JS, Mougey EH, Neta R. Synergistic roles of interleukin-6, interleukin-1, and tumor necrosis factor in the adrenocorticotropin response to bacterial lipopolysaccharide in vivo. Endocrinology 1993; 132:946-952.
88. Hermus ARM, Sweep CGJ. Cytokines and the hypothalamic-pituitary-adrenal axis. J Steroid Biochem Molec Biol 1990;37:867-871.
89. Meduri GU. The role of the host defense response in the progression and outcome of ARDS: pathophysiological correlations and response to glucocorticoid treatment. Eur Respir Journal 1996;9:2650-2670.
90. Headley AS, Tolley E, Meduri GU. Infections and the inflammatory response in acute respiratory distress syndrome. Chest 1997;111:1306-1321.
91. Christou NV. Host defense mechanisms of surgical patients: Friend or Foe? Arch Surg 1996;131:1136-1139.
92. Guirao X, Lowry SF. Biologic control of injury and inflammation: Much more than too little or too late. World J Surg 1996;20:437-446.
93. Schwartz MD, Moore EE, Moore FA, Shenkar R, Moine P, Haenel JB, Abraham E. Nuclear factor-kB is activated in alveolar macrophages from patients with acute respiratory distress syndrome. Crit Care Med 1996;24:1285-1292.
94. Maus U, Pavlidis T, Rosseau S, Seeger W, Lohmeyer J. Increased proinflammatory cytokine gene expression in alveolar macrophages is associated with changes in NF-kB DNA binding activity in septic ARDS. AJRCCM 1998;157: A459 (abstract).
95. Böhrer H, Qiu F, Zimmermann T, Zhang Y, Jllmer T, Männel D, Böttiger BW, Stern D, Waldherr R, Saeger H, Ziegler R, Bierhaus A, Martin E, Nawroth PP. Role of NF-kB in the mortality of sepsis. J Clin Invest 1997;100(5):972-984.
96. Damas P, Ledoux D, Nys M, Vrindts Y, DeGrotte D, Franchimont P, Lamy M. Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg 1992;215(4):356-362.
97. Calandra T, Gerain J, Heumann D, Baumgartner JD, Glauser MP, Swiss-Dutch J5 Immunoglobulin Study Group. High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. Am J Med 1991;91:23-29.
98. Pinski MR, Vincent JL, Deviere J, Alegre M, Kahn RJ, Dupont E. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest 1993;103:565-575.
99. Sullivan JS, Kilpatrick L, Costarino AT, Lee SC, Harris MC. Correlation of plasma cytokine elevations with mortality rate in children with sepsis. J Pediatr 1992;120:510-515.
100. Dofferhoff ASM, De Jong HJ, Bom VJJ, Van Der Meer J, Limburg PC, De Vries-Hospers HG, Marrink J, Mulder PO, Weits J. Complement activation and the production of inflammatory mediators during the treatment of severe sepsis in humans. Scand J Infect Dis 1992;24:197-204.
101. Meduri GU, Headley S, Kohler G, Stentz F, Tolley E, Umberger R, Leeper K. Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1β and IL-6 are consistent and efficient predictors of outcome overtime. Chest 1995;107:1062-1073.
102. Roumen RMH, Hendriks T, van der Ven-Jongekrijg J, Nieuwenhuijzen GAP, Sauerwein RW, van der Meer JWM, Goris RJA. Cytokine patterns in patients after major vascular surgery, hemorrhagic shock, and severe blunt trauma. Relation with subsequent adult respiratory distress syndrome and multiple organ failure. Ann Surg 1993;218(6):769-776.
103. 2 and cachectin levels in adult respiratory distress syndrome and multiple-organ failure. Clin Biochem 1992;25:55-60.
104. Groeneveld ABJ, Raijmakers PGHM, Hack Ce, Thijs LG. Interleukin 8-related neutrophil elastase and the severity of the adult respiratory distress syndrome. Cytokine 1995; 7:746-752.
105. Meduri GU, Kohler G, Headley S, Tolley E, Stentz P, Postlethwaite A. Inflammatory cytokines in the BAL of patients with ARDS. Persistent elevation over time predicts poor outcome. Chest 1995;108:1303-1314.
106. Baughman RP, Gunther KL, Rashkin MC, Keeton DA, Pattishall EN. Changes in the inflammatory response of the lung during acute respiratory distress syndrome: Prognostic indicators. Am J Resp Crit Care Med 1996;154:76-81.
107. Barnes PJ, Greening AP, Crompton GK. Glucocorticoid resistance in asthma. Am J Respir Crit Care Med 1995;152: S125-S142.
108. Bamberger CM, Shulte HM, Chrousos GP. Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids. Endocrine Reviews 1996;17: 245-261.
109. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS. Role of transcriptional activation of IkBα in medication of immunosuppression by glucocorticoids. Science 1995;270: 283-290.
110. Wissink S, van Heerde EC, van der Burg B, van der Saag PT. A dual mechanism mediates repression of NP-kB activity by glucocorticoids. Mol Endocrinol 1998;12:355-363.
111. Detera-Wadleigh SD, Karl M. The glucocorticoid receptor gene. Ann Intern Med 1993;119:1113-1124.
112. Pruzanski W, Vadas P. Phospholipase A2 - A mediator between proximal and distal effectors of inflammation. Immunol Today 1991;12:143-146.
113. Meduri GU, Belenchia JM, Estes RJ, Wunderink RG, El-Torky M, Leeper KV Jr Fibroproliferative phase of ARDS. Clinical findings and effects of corticosteroids. Chest 1991;100:943-952.
114. Santos AA, Scheltinga MR, Lynch E, Brown EP, Lawton P, Chambers E, Browning J, Dinarello CA, Wolff SM, Wilmore DW. Elaboration of interleukin 1-receptor antagonist is not attenuated by glucocorticoids after endotoxemia. Arch Surg 1993;128:138-144.
115. Hart PH, Whitty GA, Burgess DR, Croatto M, Hamilton JA. Augmentation of glucocorticoid action on human monocytes by interleukin-4. Lymphokine Res 1990;9:147-153.
116. Magiakou MA, Mastorakos G, Zachman K, Chrousos GP. Blood pressure in children and adolescents with cushing syndrome before and after surgical cure. J Clin Endocrinol Metab 1997;82:1734-1738.
117. Reincke M, Allolio B, Wurth G, Winkelmann W. The hypothalamic-pituitary-adrenal axis in critical illness: response to dexamethasone and corticotropin-releasing hormone. J Clin Endocrinol Metab 1993;77:151-156.
118. Briegel J, Horst H, Hellinger H, Haller M. Contribution of cortisol deficiency to septic shock. Lancet 1991;338:507-508.
119. Almawi WY, Lipman ML, Stevens AC, Zanker B, Hadro Er, Strom TB. Abrogation of glucocorticosteroid-mediated inhibition of T cell proliferation by the synergistic action of IL-1, IL-6, and IFN-g. J Immunol 1991;146:3523-3527.
120. Kam JC, Szefler SJ, Surs W, Sher ER, Leung DYM. Combination IL-2 and IL-4 reduces glucocorticoid receptor-binding affinity and T cell response to glucocorticoids. J Immunol 1993;151:3460-3466.
121. Spahn JD, Szefler SJ, Surs W, Doherty DE, Nimmagadda SR, Leung DYM. Induction of diminished monocyte glucocorticoid receptor-binding affinity. J Immunol 1996: 157:2654-2659.
122. 2 in sheep with acute lung injury after high dose endotoxin infusion. Am Rev Respir Dis 1993;148:878-881.
123. Fan J, Gong X, Wu J, Zhang Y, Xu R. Effect of glucocorticoid receptor (GR) blockade on endotoxemia in rats. Circulatory Shock 1994;42:76-82.
124. Molijn GJ, Spek JJ, van Uffelen JC, de Jong PH, Brinkmann AO, Bruining HA, et al. Differential adaptation of glucocorticoid sensitivity of peripheral blood mononuclear leukocytes in patients with sepsis or septic shock. J Clin Endocrinol Metab 1995;80:1799-1803.
125. Molijn GJ, Spek JJ, Van Uffelen JCJ, de Jong FH, Brinkmann AO, Bruining HA. Lamberts SWJ. Koper JW. Differential adaptation of glucocorticoid sensitivity of peripheral blood mononuclear leukocytes in patients with sepsis or septic shock. J Clin Endocrinol Metab 1995;80(6):1799-1803.
126. Leung DYM, Hamid Q, Vottero A, Szefler SJ, Surs W, Minshall E, Chrousos GP, Klemm DJ. Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor B J Exp Med 1997;186(9):1567-1574.
127. Christman JW, Lancaster LH, Blackwell TS. Nuclear factor kB: A pivotal role in the systemic inflammatory response syndrome and new target for therapy. Intens Care Med 1998;24:1131-1138.
128. Meduri GU, Headley S. Tolley E, Shelby M, Stentz P, Postlethwaite A. Plasma and BAL cytokine response to corticosteroid rescue treatment in late ARDS. Chest 1995; 108:1315-1325.
129. Hooper RG, Kearl RA. Established ARDS treated with a sustained course of adrenocortical steroids. Chest 1990;97: 138-143.
130. Barnes PJ, Adcock IM. Glucocorticoids receptors. In: Crystal RG, West JB, Weibel ER Barnes PJ. eds. The Lung Scientific Foundations. Philadelphia: Lippincott-Raven, 1997;37-55.
131. Meduri GU, Kanangat S, Stefan J, Tolley E, Schaberg D. Cytokines IL-Iβ, IL-6, and TNF-α enhance in vitro growth of bacteria. Am J Respir Crit Care Med 1999;(in press).
132. Kanangat S, Meduri GU, Tolley EA, Patterson DR, Meduri CU, Pak C, Griffin JP, Bronze MS, Schaberg DR. Effects of cytokines and endotoxin on the intracellular growth of bacteria. Infect Immun 1999;67:2834-2840.